Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. November 2018 07:00 ET | Quelle: Axsome Therapeutics, Inc.

Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference

NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
09. November 2018 07:00 ET | Quelle: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update

Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3...
01. November 2018 07:00 ET | Quelle: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018

Axsome to host conference call and webcast on Friday, November 9, 2018 at 8:00 AM Eastern Time NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
11. Oktober 2018 07:00 ET | Quelle: Axsome Therapeutics, Inc.

Axsome Therapeutics to Focus on Growing Core CNS Portfolio; Establishes Axsome Pain and Primary Care Business Unit to Enhance Value of Non-CNS Assets

Axsome PPC to include three novel, non-opioid, Phase 3-stage product candidates for chronic pain 145 issued Axsome PPC patents, including 21 covering neridronate, provide protection as far as 2036 ...